Docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer: Results from the Swedish PREDIX HER2 trial identifying a new potential de-escalation standard?

被引：16

作者：

Bergh, Jonas C. S.

Andersson, Anne

Bjohle, Judith

Bosch, Ana

Carlsson, Lena

Dreifaldt, Ann Charlotte

Einbeigi, Zakaria

Fredholm, Hanna

Isaksson-Friman, Erika

Foukakis, Theodoros

Elinder, Ellinor

Hellstrom, Mats

Johansson, Hemming

Lekberg, Tobias

Lindman, Henrik

Maes, Claudia

Brandberg, Yvonne

Hatschek, Thomas

机构：

[1] Karolinska Inst, Stockholm, Sweden

[2] Univ Hosp, Stockholm, Sweden

[3] Umea Univ, Umea, Sweden

[4] Karolinska Univ Hosp, Stockholm, Sweden

[5] Lund Univ, Ctr Canc, Lund, Sweden

[6] Cty Hosp, Sundsvall, Sweden

[7] Orebro Univ Hosp, Orebro, Sweden

[8] Sahlgrens Univ Hosp, Gothenburg, Sweden

[9] Capio St Goran, Stockholm, Sweden

[10] Soder Sjukhuset, Stockholm, Sweden

[11] Karolinska Univ Hosp, Clin Trial Unit Oncol, Stockholm, Sweden

[12] Karolinska Inst, Dept Oncol, Stockholm, Sweden

[13] Uppsala Univ Hosp, Uppsala, Sweden

[14] Karolinska Inst, Karolinska Univ Hosp, Dept Oncol Pathol OnkPat, Stockholm, Sweden

来源：

关键词：

D O I：

10.1200/JCO.2019.37.15_suppl.501

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

501

引用

页数：2